Enrollment criteria controversies for active surveillance and triggers for conversion to treatment in prostate cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 9, 2012, Pages 1101-1110

  Buethe, David D ^a   Pow Sang, Julio ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PROSTATE SPECIFIC ANTIGEN;

CANCER EPIDEMIOLOGY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; HUMAN; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; STRATIFIED SAMPLE; VALIDATION STUDY;

EID: 84866564802     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0116     Document Type: Review

References (71)

1. Choo R, Klotz L, Danjoux C, et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002;167:1664-1669.
2. Carter HB, Walsh PC, Landis P, et al. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002;167:1231-1234.
3. Cooperberg MR, Lubeck DP, Mehta SS, et al. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 2003;170:S21-25; discussion S26-27.
4. Epstein JI, Chan DW, Sokoll LJ, et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998;160:2407-2411.
5. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Canc Inst 2003;95:868-878.
6. Sakr WA, Grignon DJ, Haas GP, et al. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996;30:138-144.
7. Damiano R, Di Lorenzo G, Cantiello F, et al. Clinicopathologic features of prostate adenocarcinoma incidentally discovered at the time of radical cystectomy: an evidence-based analysis. Eur Urol 2007;52:648-657.
8. Klotz L. Cancer overdiagnosis and overtreatment. Curr Opin Urol 2012;22:203-209.
9. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-2101.
10. Barocas DA, Cowan JE, Smith JA Jr, et al. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol 2008;180:1330-1334; discussion 1334-1335.
11. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981-990.
12. Lin K, Croswell JM, Koenig H, et al. Prostate-specific antigenbased screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
13. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974.
14. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974.
15. Mohler JL, Armstrong AJ, Bahnson RR, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Prostate Cancer. Version 3, 2012. Available at: NCCN.org. Accessed July 19, 2012.
16. Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancerspecific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27:4300-4305.
17. van As NJ, Norman AR, Thomas K, et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008;54:1297-1305.
18. Dall'Era MA, Konety BR, Cowan JE, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008;112:2664-2670.
19. Eggener SE, Mueller A, Berglund RK, et al. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol 2009;181:1635-1641; discussion 1641.
20. Newcomb LF, Brooks JD, Carroll PR, et al. Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology 2010;75:407-413.
21. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term followup of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126-131.
22. Soloway MS, Soloway CT, Eldefrawy A, et al. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol 2010;58:831-835.
23. Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011;29:2185-2190.
24. Bangma CH, Bul M, Roobol M. The Prostate Cancer Research International: Active Surveillance study. Curr Opin Urol 2012;22:216-221.
25. Tseng KS, Landis P, Epstein JI, et al. Risk stratification of men choosing surveillance for low risk prostate cancer. J Urol 2010;183:1779-1785.
26. San Francisco IF, Werner L, Regan MM, et al. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol 2011;185:471-476.
27. Shariat SF, Abdel-Aziz KF, Roehrborn CG, et al. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml. Eur Urol 2006;49:293-302.
28. Khan MA, Carter HB, Epstein JI, et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 2003;170:2274-2278.
29. Raaijmakers R, de Vries SH, Blijenberg BG, et al. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml. Eur Urol 2007;52:1358-1364.
30. Southwick PC, Catalona WJ, Partin AW, et al. Prediction of postradical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. J Urol 1999;162:1346-1351.
31. Pannek J, Rittenhouse HG, Chan DW, et al. The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J Urol 1998;159:1238-1242.
32. Graefen M, Karakiewicz PI, Cagiannos I, et al. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy. J Urol 2002;167:1306-1309.
33. Bangma CH, Kranse R, Blijenberg BG, et al. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. J Urol 1997;157:544-547.
34. Cheng L, Poulos CK, Pan CX, et al. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens. J Urol 2005;174:898-902.
35. Capitanio U, Karakiewicz PI, Valiquette L, et al. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer. Urology 2009;73:1087-1091.
36. Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-374.
37. Ploussard G, Xylinas E, Salomon L, et al. The role of biopsy core number in selecting prostate cancer patients for active surveillance. Eur Urol 2009;56:891-898.
38. Berglund RK, Masterson TA, Vora KC, et al. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol 2008;180:1964-1967; discussion 1967-1968.
39. Ayres BE, Bott SR, Barber NJ, et al. Re: a multi-institutional evaluation of active surveillance for low risk prostate cancer. S. E. Eggener, A. Mueller, R. K. Berglund, R. Ayyathurai, C. Soloway, M. S. Soloway, R. Abouassaly, E. A. Klein, S. J. Jones, C. Zappavigna, L. Goldenberg, P. T. Scardino, J. A. Eastham and B. Guillonneau J Urol 2009; 181: 1635-1641. J Urol 2010;184:1223-1224; author reply 1224.
40. Bott SR, Young MP, Kellett MJ, et al. Anterior prostate cancer: is it more difficult to diagnose? BJU Int 2002;89:886-889.
41. Epstein JI, Walsh PC, Carter HB. Importance of posterolateral needle biopsies in the detection of prostate cancer. Urology 2001;57:1112-1116.
42. Duffield AS, Lee TK, Miyamoto H, et al. Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol 2009;182:2274-2278.
43. Young JL, Liss MA, Szabo RJ. Sepsis due to fluoroquinoloneresistant Escherichia coli after transrectal ultrasound-guided prostate needle biopsy. Urology 2009;74:332-338.
44. Shandera KC, Thibault GP, Deshon GE Jr. Variability in patient preparation for prostate biopsy among American urologists. Urology 1998;52:644-646.
45. Sieber PR, Rommel FM, Agusta VE, et al. Antibiotic prophylaxis in ultrasound guided transrectal prostate biopsy. J Urol 1997;157:2199-2200.
46. Feliciano J, Teper E, Ferrandino M, et al. The incidence of fluoroquinolone resistant infections after prostate biopsy-are fluoroquinolones still effective prophylaxis? J Urol 2008;179:952-955; discussion 955.
47. Wagenlehner FM, van Oostrum E, Tenke P, et al. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol, in press.
48. Mosharafa AA, Torky MH, El Said WM, et al. Rising incidence of acute prostatitis following prostate biopsy: fluoroquinolone resistance and exposure is a significant risk factor. Urology 2011;78:511-514.
49. Liss MA, Peeples AN, Peterson EM. Detection of fluoroquinoloneresistant organisms from rectal swabs by use of selective media prior to a transrectal prostate biopsy. J Clin Microbiol 2011;49:1116-1118.
50. Fujita K, Landis P, McNeil BK, et al. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol 2009;182:2664-2669.
51. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-5979.
52. Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3(PCA3)- based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-15; discussion 15-16.
53. Deras IL, Aubin SM, Blase A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008;179:1587-1592.
54. Nakanishi H, Groskopf J, Fritsche HA, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008;179:1804-1809; discussion 1809-1810.
55. Whitman EJ, Groskopf J, Ali A, et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 2008;180:1975-1978; discussion 1978-1979.
56. Aubin SM, Reid J, Sarno MJ, et al. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol 2010;184:1947-1952.
57. Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007;69:532-535.
58. Haese A, de la Taille A, van Poppel H, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008;54:1081-1088.
59. Tosoian JJ, Loeb S, Kettermann A, et al. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol 2010;183:534-538.
60. Margel D, Yap SA, Lawrentschuk N, et al. Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study. J Urol 2012;187:1247-1252.
61. Vickers AJ, Savage C, O'Brien MF, et al. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009;27:398-403.
62. Ross AE, Loeb S, Landis P, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010;28:2810-2816.
63. Whitson JM, Porten SP, Hilton JF, et al. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol 2011;185:1656-1660.
64. Carvalhal GF, Daudi SN, Kan D, et al. Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. Urology 2010;76:1072-1076.
65. Loeb S, Metter EJ, Kan D, et al. Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. BJU Int 2012;109:508-513; discussion 513-514.
66. Dall'Era MA, Cowan JE, Simko J, et al. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. BJU Int 2011;107:1232-1237.
67. van den Bergh RC, Steyerberg EW, Khatami A, et al. Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes? Cancer 2010;116:1281-1290.
68. Bul M, Zhu X, Rannikko A, et al. Radical prostatectomy for lowrisk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol 2012;62:195-200.
69. Zaytoun OM, Vargo EH, Rajan R, et al. Emergence of fluoroquinolone- resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology 2011;77:1035-1041.
70. Patel U, Dasgupta P, Amoroso P, et al. Infection after transrectal ultrasonography-guided prostate biopsy: increased relative risks after recent international travel or antibiotic use. BJU Int 2012;109:1781-1785.
71. Mosharafa AA, Torky MH, Said WM, et al. Rising incidence of acute prostatitis following prostate biopsy: fluoroquinolone resistance and exposure is a significant risk factor. Urology 2011;78:511-514.